Zealand Pharma to attend Kempen Life Sciences Conference

Press release – No. 07 / 2019

Zealand Pharma to attend Kempen Life Sciences Conference

Copenhagen, April 08, 2019 – Adam Steensberg, Interim Chief Executive Officer, will attend the Kempen Life Sciences Conference on April 16, 2019 in Amsterdam. Zealand Pharma is scheduled to present at 3:30 PM CET.

For further information, please contact:

Adam Steensberg, Interim Chief Executive Officer, Executive Vice President and Chief Medical & Development OfficerTel: +45 50 60 36 01, e-mail: [email protected] Lani Pollworth Morvan, Investor Relations and CommunicationsTel: +45 50 60 37 78, e-mail: [email protected]

About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

Attachment

• 07-19_0408_Zealand_attends_Kempen

You May Also Be Interested In

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
• British Property Entrepreneur Samuel Leeds Takes The Eviction Competition to the US for the First Texas Series
• Cogent Communications Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Cogent Communications Holdings, Inc.